March GBG Report Highlights for MichBio Members

March 17, 2025

Unlock 105 Non-Dilutive Funding Opportunities with This Month's GBG Report

This month’s GBG report offers a wealth of insight into the latest government funding landscape, featuring 105 non-dilutive opportunities, notices of special interest, and other chances to advance your work. Whether you’re a small business, a researcher, or part of a biotech organization, these opportunities could be vital in supporting your innovative projects.


Don’t Miss the GBG Monthly Webinar
Mark your calendars for Thursday, March 20, 2025, and join G2G’s Monthly GBG Reporting Service Webinar. This informative session includes two segments tailored to your needs:

  • 12-12:30 pm ET: Free and open to all, covering the latest developments in non-dilutive funding.
  • 12:30-1 pm ET: Exclusive premium service for MichBio members, providing a consultation with G2G’s experts. This segment includes new private consultation features designed to boost your funding strategy.


Navigating Ongoing Developments in Washington, DC
The funding landscape remains dynamic, with federal government priorities shifting under new executive orders. While some programs have been scaled back at institutions like the NIH, G2G continues to uncover actionable opportunities for the community. Contact Aditya Girish for deeper insights or assistance.


Highlights from the Report
The GBG report covers several standout funding opportunities across various fields, detailing the types of projects currently prioritized by agencies such as BARDA, DTRA, and PCORI. Here are some key highlights:

  • Biotechnology & Biomanufacturing: Advanced clinical testing of single-dose vaccines and improved manufacturing methods.
  • Cognitive and Brain Health: NIH Notice of Special Interest (NOSI) focusing on digital technologies that detect early changes in individuals at risk of Alzheimer’s Disease and related dementias.
  • Medical Countermeasures: DTRA seeks projects in tissue regeneration, broad-spectrum countermeasures, and chemical defense.
  • Rare Disease Research: PCORI funding for comparative effectiveness research in symptom management and care delivery.
  • Small Business Development: DoD programs, including SBIRs, target small businesses advancing medical R&D, regulatory processes, and translational science.


Additional Opportunities to Note
Outside of the main report, the ISS National Lab is seeking proposals for STEM education and workforce development projects that leverage space-based research to engage post-secondary students, K-12 students, and educators.


March 2025 Report Highlights by Category
The report provides detailed opportunities across a range of fields, including but not limited to the following categories and topics:

  • Cancer (24 opportunities)
  • Cognitive and Brain Health (7 opportunities)
  • Rare Diseases (1 opportunity)
  • Small Business Development (7 opportunities)
  • Women’s Health (2 opportunities)


With additional recurring opportunities listed for agencies such as the Advanced Research Projects Agency for Health (ARPA-H), DARPA, and BARDA, this report is packed with actionable information to help you secure funding.

Take Action Now

For a comprehensive breakdown of all 105 funding opportunities, as well as detailed insights and guidance, access the full report available exclusively to MichBio members. With funding opportunities evolving rapidly, now is the time to position your work for success.


Unlock more opportunities and gain expert tips by accessing the full report today.

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.